As of 2025-12-22, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -4.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 307.38 mil USD. Aclaris's TTM EBITDA according to its financial statements is -62.39 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 11.1x | 8.5x |
| Forward P/E multiples | 13.2x - 19.1x | 15.4x |
| Fair Price | (7.34) - (6.17) | (6.65) |
| Upside | -339.2% - -301.0% | -316.5% |
| Date | EV/EBITDA |
| 2025-12-19 | -5.05 |
| 2025-12-18 | -4.94 |
| 2025-12-17 | -4.86 |
| 2025-12-16 | -5.17 |
| 2025-12-15 | -5.10 |
| 2025-12-12 | -5.24 |
| 2025-12-11 | -5.43 |
| 2025-12-10 | -5.27 |
| 2025-12-09 | -5.17 |
| 2025-12-08 | -5.29 |
| 2025-12-05 | -4.67 |
| 2025-12-04 | -4.82 |
| 2025-12-03 | -4.42 |
| 2025-12-02 | -4.28 |
| 2025-12-01 | -4.13 |
| 2025-11-28 | -4.51 |
| 2025-11-26 | -4.60 |
| 2025-11-25 | -4.34 |
| 2025-11-24 | -4.37 |
| 2025-11-21 | -3.95 |
| 2025-11-20 | -3.78 |
| 2025-11-19 | -3.87 |
| 2025-11-18 | -3.92 |
| 2025-11-17 | -3.85 |
| 2025-11-14 | -3.97 |
| 2025-11-13 | -3.62 |
| 2025-11-12 | -3.78 |
| 2025-11-11 | -3.59 |
| 2025-11-10 | -3.29 |
| 2025-11-07 | -3.62 |
| 2025-11-06 | -3.54 |
| 2025-11-05 | -3.52 |
| 2025-11-04 | -3.69 |
| 2025-11-03 | -4.04 |
| 2025-10-31 | -3.97 |
| 2025-10-30 | -3.92 |
| 2025-10-29 | -3.66 |
| 2025-10-28 | -3.75 |
| 2025-10-27 | -3.66 |
| 2025-10-24 | -3.33 |
| 2025-10-23 | -3.52 |
| 2025-10-22 | -3.52 |
| 2025-10-21 | -3.73 |
| 2025-10-20 | -3.09 |
| 2025-10-17 | -2.90 |
| 2025-10-16 | -3.16 |
| 2025-10-15 | -2.95 |
| 2025-10-14 | -2.74 |
| 2025-10-13 | -2.91 |
| 2025-10-10 | -2.84 |